Enveda nabs $311m to progress nature-derived drug pipeline - Pharmaceutical Technology

The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders. The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders. Enveda will progress three clinical-stage candidates, as well as 14 other assets that have not yet made it to the clinic. Credit: Visual Generation / Shutterstock.com. Colorado-based biotech Enveda has closed a $311m Series E funding round to advance its pipeline of artificial intelligence (AI)-discovered therapies for inflammatory and metabolic disorders – taking its total raised to more than $845m. Through this financing, which was led…

Source: Pharmaceutical Technology